| abstract |
This disclosure is directed to compositions for targeting sub histocompatibility (H) antigens (HA-1H?), For example, to prevent or manage the recurrence of hematologic malignancy following allogeneic hematopoietic stem cell transplantation (HCT) And methods. Also provided is a transgenic construct that encodes an engineered binding protein, such as a T cell receptor or chimeric antigen receptor, and optionally encodes additional components such as a co-receptor and / or a stability switch. Such a transgene construct may be transfected into an immune cell, such as a T cell, to be used as an immunotherapy in a subject having a hematologic malignancy or at risk of recurrence of hematologic malignancies (e.g., leukemia, lymphoma, myeloma) . |